Connect with us

Health Care

Anteris Technologies (ASX:AVR) – Wayne Paterson

Published

on

The CEO Mindset - Wayne Paterson is the Chief Executive Officer of Anteris Technologies Ltd (ASX:AVR)

Wayne Paterson is the Chief Executive Officer of Anteris Technologies Ltd (ASX:AVR), a structural heart company. The company’s core technology is its ADAPT® tissue technology. Initially commercialized to treat congenital heart defects, ADAPT® is the only engineered tissue with clinical data to support ten years of anti-calcification.

Anteris Technologies is now focused on the development of next-generation technologies using its ADAPT® tissue. Its 3D single-piece aortic valve DurAVR™ combines the clinical superiority of ADAPT® with a groundbreaking design, to create the world’s most durable aortic heart valve, for the treatment of aortic stenosis, one of the most common forms of heart valve disease affecting people over the age of 65.

What’s your journey in becoming a CEO?
I left Australia over 20 years ago, and during that time I have had the privilege of working and living in seven different countries. Working in Big Pharma, I was promoted to roles of ever-increasing revenue and human resource responsibility. I went from heading up commercial operations in China for Roche, to CEO roles in Korea and Japan. As well holding CEO roles for whole regions (emerging markets), and then finally CEO of Europe where I managed 30 countries and billions in revenue, I also held the role of Global Head of Cardiovascular Medicine for a major pharma company. Each one of these roles gave me insights to operations, national cultures, performance metrics and health care systems all over the world.

Tell us a bit about your business and how you are commercializing?
Anteris is a structural heart company that has a novel and unique technology, ADAPT®, which is backed by validated and widely published science. The market space we are addressing has a value of more than US$8 bn and we are well on the path to registration at the moment, conducting clinical trials for our 3D single-piece aortic valve DurAVR™, that will lead to regulatory approval and commercialization. Commercialization of our TAVR (transcatheter aortic valve replacement) device will be in partnership with one of the major companies in the MedTech space.

How are you managing with the current COVID-19 pandemic on both business and personal front?
Due to the restructure that we completed last year, we are in a good position from a business perspective. Our operations have seen little to no impact and we are on track with our 2020 plan. On a personal front, the current COVID-19 pandemic presents its challenges as the role of the CEO is very much a face to face and hands on role. Whether it’s with staff, funds or other stakeholders that we deal with, we have managed to do most things remotely. Due to the time zones we operate across (my usual day goes from about 8am to 10pm), and because we have all staff working from home, I am able to do a lot of my work from the office alone and this has been very valuable.

What’s the most exciting thing about running your business?
The Anteris team inspire me and the science excites me. It is increasingly apparent that we have real clinical benefits above and beyond what’s currently in the market and the knowledge that we will bring this to patients all over the world in the near future is very exciting.

How do you measure success?
There are 3 key areas that I consider are markers of success.

1) Developing a team of engaged, high performing and motivated individuals which leads to;
2) developing science and products that are significant, clinically superior and high value, which leads to;
3) higher shareholder returns

What do you think is the most important quality of being a CEO of a listed company?
High work ethic, transparency, and integrity.

What is your favourite book? 
I have two. Authentic Leadership by Bill George (former CEO of Medtronic) and the book I give all my executives is the Art of War by Sun Tzu.

What message do you want to send to our readership in Asia?
Having lived in China, Korea, Singapore and Japan, I have a huge affiliation for the talent, drive and work ethic in Asia. My message to the region is to keep embracing the opportunities that the highest growing markets bring, and to keep innovating! I am confident that when we launch our TAVR product into the region, it will be highly successful due to the skills and drive of the teams in this region.

How can people connect with you?
Email: WE-AUAnterisTech@we-worldwide.com
Website: https://anteristech.com/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

AVR’s CEO Wayne Paterson During A Patient’s Heart Surgery

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health Care

Q&A with StockPal – Althea Group Holdings (ASX:AGH)

Published

on

Q&A with StockPal - Joshua Fegan, CEO/Managing Director/Founder of Althea Group Holdings (ASX:AGH)

Watch Joshua Fegan, CEO/Managing Director/Founder of Althea Group Holdings (ASX:AGH) and Jared Sim, Editor-in-Chief and Co-Founder of StockPal in this engaging Q&A with the following questions:

0:08 – How did your company cope with the COVID-19 pandemic?
2:31 – When did the company list and why?
3:35 – How does your company make money?
4:22 – Who are your target customers?
5:23 What is your firm’s competitive advantage?

Visit Althea’s website to learn more about their story: https://althea.life/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Health Care

Q&A with StockPal – Aptorum Group (NASDAQ:APM)

Published

on

Q&A with StockPal - Darren Lui, President and Executive Director of Aptorum Group (NASDAQ:APM)

Watch Darren Lui, President and Executive Director of Aptorum Group (NASDAQ:APM) and Jared Sim, Editor-in-Chief and Co-Founder of StockPal in this engaging Q&A with the following questions:

0:09 – How did Aptorum cope with the COVID-19 pandemic?
1:09 – When did Aptorum list and why?
2:50 – How does the company make money?
5:41 – Who are your target investors?
7:41 – What is Aptorum’s competitive advantage?
9:48 – What keeps you most excited about being in Aptorum?
12:50 – How do you measure success?

Visit Aptorum’s website to learn more about their story: https://www.aptorumgroup.com/

Email editor@stockpal.asia if you are or represent a listed-company and is keen to be in our interviews.

Continue Reading

Health Care

Q&A with StockPal – Antisense Therapeutics Limited (ASX:ANP)

Published

on

Q&A with StockPal - Mark Diamond, Managing Director & CEO of Antisense Therapeutics Limited (ASX:ANP)

Watch Jared Sim, Editor-in-Chief and Co-Founder of StockPal and Mark Diamond, Managing Director & CEO of Antisense Therapeutics Limited (ASX:ANP) in this engaging Q&A with the following questions:

0:16 – How did your company cope with the COVID-19 pandemic?
1:03 – When did the company list and why?
2:10 – How does your company make money?
3:05 – Who are your target customers?
4:13 – What is your firm’s competitive advantage?

Visit Antisense’s website to learn more about their story: https://www.antisense.com.au/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Get more stuff

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Recent Posts

Categories

Trending